86 related articles for article (PubMed ID: 34178624)
1. Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With
Niu X; Sun Y; Planchard D; Chiu L; Bai J; Ai X; Lu S
Front Oncol; 2021; 11():634920. PubMed ID: 34178624
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for patients with advanced non-small cell lung cancer harboring oncogenic driver alterations other than
Tian T; Li Y; Li J; Xu H; Fan H; Zhu J; Wang Y; Peng F; Gong Y; Du Y; Yan X; He X; Cali Daylan AE; Pircher A; Neibart SS; Okuma Y; Hong MH; Huang M; Lu Y
Transl Lung Cancer Res; 2024 Apr; 13(4):861-874. PubMed ID: 38736501
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of non-small cell lung cancer patients with non-V600E
Lazar R; Fischbach C; Schott R; Somme L
Front Oncol; 2024; 14():1307882. PubMed ID: 38601760
[TBL] [Abstract][Full Text] [Related]
4. Current state of immunotherapy for non-small cell lung cancer.
Malhotra J; Jabbour SK; Aisner J
Transl Lung Cancer Res; 2017 Apr; 6(2):196-211. PubMed ID: 28529902
[TBL] [Abstract][Full Text] [Related]
5. Partial response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic
Huang Y; Zhang S; Hu X; Wang X; Zhao Y; Li Z
AME Case Rep; 2024; 8():38. PubMed ID: 38711893
[TBL] [Abstract][Full Text] [Related]
6. Case report: Dual dabrafenib and trametinib therapy for treating BRAF V600E mutated lung adenocarcinoma with BRCA2 germline mutation post multiline progression.
Zhang H; Cong X; Yin J; Chen C; Liu Z
Front Oncol; 2024; 14():1387388. PubMed ID: 38715777
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological Features of Non-Small Cell Lung Carcinoma with BRAF Mutation.
Ambrosini-Spaltro A; Rengucci C; Capelli L; Chiadini E; Calistri D; Bennati C; Cravero P; Limarzi F; Nosseir S; Panzacchi R; Valli M; Ulivi P; Rossi G
Curr Oncol; 2023 Nov; 30(11):10019-10032. PubMed ID: 37999148
[TBL] [Abstract][Full Text] [Related]
8. A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma.
Von CE; Fuang HG
Respir Med Case Rep; 2021; 34():101478. PubMed ID: 34336591
[TBL] [Abstract][Full Text] [Related]
9. MAP2K1 K57N Conferred an Acquired Resistance to Furmonertinib, Dabrafenib and Trametinib Combined Therapy in Advanced Lung Adenocarcinoma with EGFR Mutation and BRAF V600E.
Tan X; Wu Z; Chen M
Onco Targets Ther; 2024; 17():307-312. PubMed ID: 38617091
[TBL] [Abstract][Full Text] [Related]
10. Upfront liquid next-generation sequencing in treatment-naïve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system.
Yang CY; Shih JY; Liao WY; Ho CC; Hsu CL; Tsai TH; Wu SG; Lin YT; Hsu WH; Jain S; Olsen S; Yang JC; Yu CJ; Yang PC
Eur J Cancer; 2023 Nov; 193():113310. PubMed ID: 37722270
[TBL] [Abstract][Full Text] [Related]
11. Effective Treatment of Lung Adenocarcinoma With a Novel SLC44A1-BRAF Fusion Using Pembrolizumab Followed by Trametinib: A Case Report.
Yasui S; Honda T; Onishi I; Ikeda S; Miyazaki Y
Cureus; 2024 Feb; 16(2):e54739. PubMed ID: 38523924
[TBL] [Abstract][Full Text] [Related]
12. Clinical Outcomes of PD-1/PD-L1 Inhibitors Among Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With BRAF, ERBB2/HER2, MET , or RET Alterations: A Systematic Literature Review.
Akers KG; Oskar S; Zhao B; Frederickson AM; Arunachalam A
J Immunother; 2024 May; 47(4):128-138. PubMed ID: 38112201
[TBL] [Abstract][Full Text] [Related]
13. Clinical Characteristics, Response to Platinum-Based Chemotherapy and Poly (Adenosine Phosphate-Ribose) Polymerase Inhibitors in Advanced Lung Cancer Patients Harboring BRCA Mutations.
Arnon J; Tabi M; Rottenberg Y; Zick A; Blumenfeld P; Hamburger T; Pikarsky E; Avraham E; Levine L; Popovtzer A; Yablonski-Peretz T; Kadouri L; Nechushtan H
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835426
[TBL] [Abstract][Full Text] [Related]
14. Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer.
Mezquita L; Oulhen M; Aberlenc A; Deloger M; Aldea M; Honore A; Lecluse Y; Howarth K; Friboulet L; Besse B; Planchard D; Farace F
Br J Cancer; 2024 Mar; 130(4):682-693. PubMed ID: 38177660
[TBL] [Abstract][Full Text] [Related]
15. BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective.
Yan N; Guo S; Zhang H; Zhang Z; Shen S; Li X
Front Oncol; 2022; 12():863043. PubMed ID: 35433454
[TBL] [Abstract][Full Text] [Related]
16. BRAF
Planchard D; Sanborn RE; Negrao MV; Vaishnavi A; Smit EF
NPJ Precis Oncol; 2024 Apr; 8(1):90. PubMed ID: 38627602
[TBL] [Abstract][Full Text] [Related]
17. Rare Driver Mutations in Advanced, Oncogene-Addicted Non-Small Cell Lung Cancer: A North Italian, Real-World, Registry Experience.
Andrikou K; Ulivi P; Petracci E; Azzali I; Bertolini F; Alberti G; Bettelli S; Calistri D; Chiadini E; Capelli L; Cravero P; Guaitoli G; Zanelli F; Burgio MA; Pagano M; Verlicchi A; Martinelli E; Di Emidio K; Dominici M; Pinto C; Delmonte A
Diagnostics (Basel); 2024 May; 14(10):. PubMed ID: 38786322
[TBL] [Abstract][Full Text] [Related]
18. The Role of Dynamic ctDNA Monitoring During Combination Therapies of BRAF V600E-Mutated Metastatic Colorectal Cancer: A Case Report.
Wang Z; Ye CY; Zhou WL; Wang MM; Dai WP; Zheng J; Zang YS
Onco Targets Ther; 2020; 13():11849-11853. PubMed ID: 33235471
[TBL] [Abstract][Full Text] [Related]
19. Editorial: Molecular genetic testing and emerging targeted therapies for non-small cell lung cancer.
Ferreira CG; Reis MX; Veloso GGV
Front Oncol; 2023; 13():1308525. PubMed ID: 38074696
[No Abstract] [Full Text] [Related]
20. Personalized therapy guided by longitudinal liquid biopsies for treatment of leptomeningeal disease from lung adenocarcinoma: A case report.
Lai M; Mu T; Liu M; Hu Q; Li J; Huang T; Li Y; Chen S; Cai L
Oncol Lett; 2024 Jul; 28(1):299. PubMed ID: 38751754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
